Neuroendocrine Tumors of Old Patients in the West of France (TANGO)
Neuroendocrine Tumors of Patients Aged of 75 y or Over in the West of France
Neuroendocrine cancer remains a poorly known entity. Comprehensive treatment is multidisciplinary involving surgery, radiological and nuclear medicine, and medical. A national network for the management of sporadic and hereditary malignant neuro-ENdocrine Tumor (RENATEN) is in charged of coordinating this specific care. This is part of the French National Cancer INstitute (INCa) Rare Cancer Plan.
The project is in the form of an analysis of elderly population (75 years or over) with a diagnosis of neuroendocrine cancer in the western part of the France (Brittany, Pays de Loire, Normandy, Center and a part of New Aquitaine areas) representing a population of more than 12 millions of inhabitants. Oncogeriatric evaluations, specialized meetings, ...would be analysed in order to improve the care of rare cancer patients.
研究概览
地位
条件
研究类型
注册 (预期的)
联系人和位置
学习地点
-
-
-
Brest、法国、29609
- CHRU de Brest
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- 75 years old or over at the time of diagnosis
- Patient with G1/G2/G3 neuroendocrine tumor diagnosed by pathological analysis
- Patient whose medical file was examined by RENATEN (National Network for the treatment of neuro-ENdocrine sporadic and hereditary disease Tumor) meetings or other multidisciplinary consultation meeting between 01/01/2014 and 31/12/2017
- Patient with care in private and public centers in the West of France
Exclusion Criteria:
- Patient with cancer other than a neuroendocrine tumor
- Patient with a G4 neuroendocrine tumor
- Patient who has objected to the study and collection of his medical data
- Refusal of participation
学习计划
研究是如何设计的？
设计细节
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Tumor description : localization of the tumor (digestive or others) provided by scan or anatomopathologic report
大体时间：03/31/2020
|
statistical analysis (%)
|
03/31/2020
|
|
All anticancer treatment description in neuroendocrine tumors of 3 specific histological grade (G1, 2 or 3)
大体时间：03/31/2020
|
statistical analysis (%)
|
03/31/2020
|
|
Histology, differentiation status
大体时间：03/31/2020
|
qualitative description (text)
|
03/31/2020
|
|
mitotic index and proliferation idex of the tumor
大体时间：03/31/2020
|
statistical analysis (%)
|
03/31/2020
|
|
Response rate
大体时间：03/31/2020
|
statistical analysis (%)
|
03/31/2020
|
|
progression free survival
大体时间：03/31/2020
|
statistical analysis (months) with Kaplan meier analysis; data provided by the medical file
|
03/31/2020
|
|
overall survival
大体时间：03/31/2020
|
statistical analysis (months) with Kaplan meier analysis; data provided by the medical file
|
03/31/2020
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (预期的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- TANGO (29BRC18.0013)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.